PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG–Avid Discordant Findings

Ridvan Arda Demirci; Alireza Ghodsi; Roman Gulati; Sanaz Behnia; Peter S. Nelson; Heather H. Cheng; Todd A. Yezefski; Michael C. Haffner; Jessica E. Hawley; Robert B. Montgomery; Evan Y. Yu; Michael T. Schweizer; Delphine L. Chen; Amir Iravani

doi:10.2967/jnumed.124.268167

Research ArticleClinical Investigation

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG–Avid Discordant Findings

Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S. Nelson, Heather H. Cheng, Todd A. Yezefski, Michael C. Haffner, Jessica E. Hawley, Robert B. Montgomery, Evan Y. Yu, Michael T. Schweizer, Delphine L. Chen and Amir Iravani

Journal of Nuclear Medicine January 2025, 66 (1) 47-53; DOI: https://doi.org/10.2967/jnumed.124.268167

Ridvan Arda Demirci

1Department of Radiology, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alireza Ghodsi

1Department of Radiology, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Roman Gulati

2Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sanaz Behnia

1Department of Radiology, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter S. Nelson

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington;

5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heather H. Cheng

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Todd A. Yezefski

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael C. Haffner

5Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington; and

6Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jessica E. Hawley

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert B. Montgomery

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Evan Y. Yu

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael T. Schweizer

3Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington;

4Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Delphine L. Chen

1Department of Radiology, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amir Iravani

1Department of Radiology, University of Washington, Seattle, Washington;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 1

January 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG–Avid Discordant Findings

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG–Avid Discordant Findings

Journal of Nuclear Medicine Jan 2025, 66 (1) 47-53; DOI: 10.2967/jnumed.124.268167

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Journal of Nuclear Medicine Jan 2025, 66 (1) 47-53; DOI: 10.2967/jnumed.124.268167

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy

Google Scholar

Keywords

prostate cancer
18F-FDG PET
PSMA PET
177Lu-PSMA
eligibility criteria; discordant disease

Main menu

User menu

Search

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG–Avid Discordant Findings

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords